Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D.
Quart, PharmD, Ardea’s president and chief executive officer, will
present at the 4th Annual Piper Jaffray Europe Conference.
Presentation details are as follows:
|
Date:
|
|
Tuesday, June 23, 2009
|
|
Time:
|
|
4:00 p.m. British Summer Time
|
|
Location:
|
|
The ANdAZ London Hotel, London, England
|
|
Webcast:
|
|
http://www.piperjaffray.com/conferences
|
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the development of small-molecule therapeutics for
the treatment of gout, cancer, inflammatory diseases and human
immunodeficiency virus (HIV). RDEA594, our lead product candidate for
the treatment of hyperuricemia and gout, is a selective URAT1
transporter inhibitor that has successfully completed single- and
multiple-ascending-dose Phase 1 studies in normal, healthy volunteers
and is being evaluated in a Phase 2a proof-of-concept study. RDEA119, a
potent and specific inhibitor of mitogen-activated ERK kinase (MEK) and
our lead product candidate for the treatment of cancer, is being
developed under a global license agreement with Bayer HealthCare.
RDEA119 is being evaluated as a single agent in a Phase 1 study in
advanced cancer patients and in a Phase 1/2 study in combination with
sorafenib (Nexavar®; Bayer HealthCare, Onyx Pharmaceuticals)
in advanced cancer patients. RDEA119 has also been evaluated for
potential use in inflammatory diseases in a Phase 1 study in normal
healthy volunteers. RDEA806, our lead product candidate for the
treatment of HIV, is a non-nucleoside reverse transcriptase inhibitor
(NNRTI) that has successfully completed a Phase 2a study in HIV patients.
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because
such statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding our plans and goals, the expected
properties and benefits of RDEA594, RDEA119, RDEA806, and our other
compounds and the timing and results of our preclinical, clinical and
other studies. Risks that contribute to the uncertain nature of
the forward-looking statements include risks related to the outcome of
preclinical and clinical studies, risks related to regulatory approvals,
delays in commencement of preclinical and clinical studies, costs
associated with our drug discovery and development programs, and risks
related to the outcome of our business development activities. These
and other risks and uncertainties are described more fully in our most
recently filed SEC documents, including our Annual Report on Form 10-K
and our Quarterly Reports on Form 10-Q, under the headings "Risk
Factors." All forward-looking statements contained in this
press release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were made.
Ardea Biosciences, Inc.
John Beck, 858-652-6523
jbeck@ardeabio.com
